Finally, the real-world experience in EGFR-mutated NSCLC demonstrated that sequential afatinib and osimertinib was beneficial in prolonging the chemotherapy-free interval in patients with T790M acquired resistance (156). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.